Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man.
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007413:Intestinal Mucosa / Q000201:enzymology; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use / Q000652:urine; D008297:Male; D008333:Mandelic Acids / Q000652:urine; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D009474:Neurons / Q000201:enzymology*; D009638:Norepinephrine / Q000378:metabolism; D009647:Normetanephrine / Q000652:urine; D013564:Sympathetic Nervous System / Q000201:enzymology*; D014363:Tryptamines / Q000652:urine; D014439:Tyramine / Q000378:metabolism / Q000652:urine; D014642:Vanilmandelic Acid / Q000652:urine
D007546:Isoquinolines; D008333:Mandelic Acids; D008996:Monoamine Oxidase Inhibitors; D014363:Tryptamines; D009647:Normetanephrine; D014642:Vanilmandelic Acid; D003404:Creatinine; D009638:Norepinephrine; D014439:Tyramine